Skip to main content

The medicines business | A question to investigate

The lowest price is only one part of the tender

A medicines tender asks for a price, but the buying decision also carries assumptions about capacity, continuity and implementation. A supplier can win an attractive contract and then discover that the delivery conditions require a different operating model. A buyer can secure a competitive offer while retaining a fragile supply position. NEUVIOR is interested in the evidence that helps both sides examine those assumptions before commitment.

Film credits

In the conversation.

NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.

University of Warwick IATL | AI Ethics NowpharmaphorumTechRadar ProET PharmaFinancial TimesPharmaceutical TechnologyPharmaTimesManufacturing ChemistDigital HealthDaily BusinessTheBusinessDesk.comStartups MagazineInsider MediaYorkshire PostYork PressBusinessCloud

Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.

Make the trade-off explicit

Tender teams often need to balance affordability, service expectations, volume uncertainty and credible supply commitments. These considerations should not be collapsed into an unexplained score. A decision paper ought to show which requirements are mandatory, which criteria can legitimately be weighted and which uncertainties remain outside the scoring model. It should also make visible whether an attractive commercial term depends on an operational change that has not yet been agreed or funded.

Understand the procurement setting

NHS England’s medicines procurement team establishes commercial arrangements for hospital medicines in England and supports supply-chain management (NHS England, n.d.). MHRA’s GDP guidance addresses distribution conditions (MHRA, 2014). Those responsibilities frame different parts of a tender discussion. A proposed commercial review would not certify a supplier, determine legal procurement compliance or substitute for quality due diligence. It would help the designated team organise the evidence required for its own purchasing or bidding decision.

Compare offers on the same basis

An offer for a different pack, minimum order, delivery frequency or notice period is not simply a different unit price. The comparison should specify the same intended demand, geography, transition period and service requirements. Where terms differ, their consequences should be presented separately rather than forced into a misleading like-for-like table. Confidential rebates, framework conditions and buyer-specific arrangements must remain within the permissions of the parties entitled to use them.

A comparison that travels beyond procurement

The proposed output would connect each commercial term to its operational condition, so that pharmacy, finance and supply colleagues can examine the same decision. Where two offers cannot be compared directly, it would explain why. The buyer or bidder could then seek the missing clarification before a preferred option becomes an irrevocable commitment.

A public decision brief | An illustrative example

Open the question.
Inspect the reasoning.

Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.

A medicines or implementation team considering an AI-supported evidence review.

Would a quicker review make the decision better?

The interesting question is the complete piece of work: finding relevant material, checking it, correcting the draft and reaching an accountable decision.

A proposition to investigate

Less preparation. The same ability to challenge.

An evidence-review approach could be useful if it reduces avoidable preparation while preserving source access, relevant qualifications and professional checking. That is the proposed value to test. No time reduction, accuracy improvement or customer result is asserted in this example.

The proposition is constructed for this public brief. It is not a published finding about PHARMORIS.

What the next brief would contain

A decision someone
can commission.

The decision
Whether one defined review task merits an agreed evaluation.
The comparator
The team's existing complete review process, including checking and corrections.
The evidence
Representative cases, source records, reviewer decisions, complete-task effort and exceptions.
Stop or redesign
Stop or redesign if source checking weakens, errors are unacceptable or the complete task offers insufficient value.

Constructed public example | Not PHARMORIS-generated software output or a measured customer result.

Keep this example brief

A proposed evaluation before a wider commitment

NEUVIOR could explore one completed tender or a permitted upcoming decision that is not subject to inappropriate access restrictions. Inputs might include approved specifications, anonymised commercial scenarios, permitted service history and capacity assumptions. The comparator would be the current bid-review or procurement paper. PHARMORIS evaluation would concern the clarity and consistency of the evidence brief, with no automated award recommendation and no exchange of competitively sensitive information between suppliers.

What a useful result looks like

Candidate measures include inconsistent assumptions discovered before sign-off, reviewer time needed to reconcile terms and the proportion of material dependencies assigned to an owner. Scenario analysis could show how a demand change alters the relative attractiveness of an offer. It should not present a hypothetical avoided disruption as realised savings. A later follow-up might compare delivery against agreed expectations, provided the terms and available evidence allow a fair assessment.

When further work is not justified

We would stop if access to tender information is inappropriate, if offers cannot be compared without prohibited disclosure, or if the apparent value depends on ignoring a mandatory requirement. An evaluation should also pause where the organisation has no authority to change the decision it is studying. A well-presented insight has little commercial value when nobody can act on it. The scope must therefore include the decision rights and the practical window for action.

A discussion for buyers and suppliers

For a hospital procurement team, the starting point may be a difficult comparison between credible offers. For an industry bid team, it may be a contract whose delivery assumptions need scrutiny. Bring one decision, its constraints and the evidence currently used. We can discuss whether a bounded review could make the trade-offs easier to inspect and help the accountable team enter a commercial commitment with a more complete understanding of what it requires.

Sources and scope

NHS England | Medicines procurement and supply chain | MHRA | Good manufacturing and distribution practice

Discuss a tender comparison

NHS England (n.d.) Medicines procurement and supply chain. Available at: https://www.england.nhs.uk/medicines-2/medicines-value-and-access/medicines-procurement-and-supply-chain/ (Accessed: 14 October 2026).

MHRA (2014) Good manufacturing and distribution practice. Available at: https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice (Accessed: 14 October 2026).

Another useful angle.

NEWSPerspectives & features
Open newsroom